Headlines about GW Pharmaceuticals PLC (NASDAQ:GWPH) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GW Pharmaceuticals PLC earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.6867248715517 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern’s analysis:
- Bank of America Corporation Lowers GW Pharmaceuticals PLC (GWPH) Price Target to $158.00 (americanbankingnews.com)
- Can GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Move Towards North? – MMJ Observer (mmjobserver.com)
- 7 Marijuana Stocks to Buy That Won’t Burn You | InvestorPlace – Investorplace.com (investorplace.com)
- GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Releases An Update On NDA Filing Of Epidiolex® – MMJ Reporter (mmjreporter.com)
A number of research firms recently commented on GWPH. Maxim Group set a $135.00 target price on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Monday, August 7th. Zacks Investment Research cut GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Cantor Fitzgerald set a $208.00 target price on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $124.00 target price on shares of GW Pharmaceuticals PLC in a research note on Friday, October 6th. Finally, Bank of America Corporation reduced their target price on GW Pharmaceuticals PLC from $160.00 to $158.00 and set a “buy” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $144.55.
Shares of GW Pharmaceuticals PLC (NASDAQ GWPH) traded up $0.33 during trading hours on Thursday, hitting $117.55. The stock had a trading volume of 523,591 shares, compared to its average volume of 318,985. GW Pharmaceuticals PLC has a 52-week low of $92.65 and a 52-week high of $136.95. The company has a current ratio of 10.39, a quick ratio of 10.26 and a debt-to-equity ratio of 0.02.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2017/11/16/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-gw-pharmaceuticals-plc-gwph-share-price.html.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.